AbbVie (NYSE:ABBV) has announced new data from a Phase 2 study of navitoclax with ruxolitinib in patients with myelofibrosis, a rare bone marrow cancer.
The data indicate that the combination therapy induces cell death, potentially leading to the reversal of bone marrow fibrosis and improving survival for patients who respond to the therapy.
The study found that 12 out of 32 patients had improvements in bone marrow fibrosis. To date, however, the study did not reach the median overall survival for the overall survival.
The company presented the results at the American Association for Cancer Research annual meeting (AACR 2022, abstract #LB108).
Navitoclax is a small-molecule-based, experimental, novel oral BCL-XL/BCL-2 inhibitor designed to activate programmed cell death (apoptosis) in cancer cells.
Overall, Navitoclax has been the subject of 39 trials to date.
North Chicago, Illinois–based AbbVie presented the results at AACR 2022 fr…